A. Aouba, M. Eb, G. Pavillon, and E. Jougla, Données sur la mortalité en France : principales causes de décès en, 2008.

M. Cournot, J. Cambou, S. Quentzel, and N. Danchin, Key factors associated with the underprescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys, Int J Cardiol, vol.111, issue.1, pp.12-20, 2006.

N. P. Chokshi, F. H. Messerli, D. Sutin, A. A. Supariwala, and N. R. Shah, Appropriateness of Statins in Patients Aged ?80 Years and Comparison to Other Age Groups, Am J Cardiol, vol.110, pp.1477-81, 2012.

E. Gremeaux, M. Grino, C. Molines, C. Oliver, and F. Retornaz, Cardiovascular secondary prevention by statin in southern french nursing home, J Nurs Home Res Sci, vol.2, pp.1-6, 2016.

, du collège de la Haute Autorité de santé portant adoption de la fiche mémo intitulée « Principales dyslipidémies : stratégies de prise en charge », de son rapport d'élaboration et de sa synthèse

R. Hammami, J. Jdidi, and F. Triki, Place des statines chez le sujet âgé, Thérapie, 2016.

. Disponible,

F. Bonnet, Faut-il arrêter les statines chez les personnes âgées ? Rev Méd Interne, 2017.

. Disponible,

F. Retornaz, S. Beliard, and E. Gremeaux, Statine et pathologies cardiovasculaires après 75 ans, Rev Méd Interne, vol.37, pp.625-656, 2016.

J. M. Jacobs, A. Cohen, E. Ein-mor, J. Stessman, and . Cholesterol, Statins, and Longevity From Age 70 to 90 Years, J Am Med Dir Assoc, vol.14, pp.883-891, 2013.

D. Agostino, R. B. Grundy, S. Sullivan, L. M. Wilson, and P. , CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation, JAMA, vol.286, pp.180-187, 2001.

L. K. Petersen, K. Christensen, and J. Kragstrup, Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds, Age Ageing, vol.39, pp.674-80, 2010.

G. Charach, A. Rabinovich, and A. Ori, Low Levels of Low-Density Lipoprotein Cholesterol: A Negative Predictor of Survival in Elderly Patients with Advanced Heart Failure, Cardiology, vol.127, pp.45-50, 2014.

O. Santana, S. Gomez, C. Mihos, and A. Pineda, The pleiotropic effects of the hydroxy-methylglutaryl-CoA reductase inhibitors in renal disease, Int J Nephrol Renov Dis, vol.123, 2014.

P. M. Ridker, E. Danielson, and F. Fonseca, Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, N Engl J Med, vol.359, pp.2195-207, 2008.

F. Taylor, M. D. Huffman, and A. F. Macedo, Statins for the primary prevention of cardiovascular disease, 2013.

S. Yusuf, J. Bosch, and G. Dagenais, Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease, N Engl J Med, vol.374, pp.2021-2052, 2016.

J. Shepherd, G. J. Blauw, and M. B. Murphy, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet Lond Engl, vol.360, pp.1623-1653, 2002.

R. J. Glynn, Rosuvastatin for Primary Prevention in Older Persons With Elevated CReactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial, Ann Intern Med, vol.152, p.488, 2010.

G. Savarese, A. M. Gotto, and S. Paolillo, Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease, J Am Coll Cardiol, vol.62, pp.2090-2099, 2013.

A. Alperovitch, T. Kurth, and M. Bertrand, Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study, BMJ, vol.350, p.2335, 2015.

J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. De-craen et al., Statins for Secondary Prevention in Elderly Patients, J Am Coll Cardiol, vol.51, pp.37-45, 2008.

P. Amarenco, O. Benavente, and L. B. Goldstein, Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes, Stroke, vol.40, pp.1405-1414, 2009.

C. Hjalmarsson, L. Bokemark, K. Manhem, K. Mehlig, and B. Andersson, The Effect of Statins on Acute and Long-Term Outcome After Ischemic Stroke in the Elderly, Am J Geriatr Pharmacother, vol.10, pp.313-335, 2012.

A. Maycock, C. A. Muhlestein, J. B. Horne, and B. D. , Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients, J Am Coll Cardiol, vol.40, pp.1777-85, 2002.

K. Gränsbo, O. Melander, and L. Wallentin, Cardiovascular and Cancer Mortality in Very Elderly Post-Myocardial Infarction Patients Receiving Statin Treatment, J Am Coll Cardiol, vol.55, pp.1362-1371, 2010.

M. Foody, J. Rathore, S. S. Galusha, and D. , Hydroxymethylglutaryl-CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an AgeStatin Interaction: STATINS AND MORTALITY IN OLDER PERSONS WITH AMI, J Am Geriatr Soc, vol.54, pp.421-451, 2006.

H. V. Ganga, H. B. Slim, and P. D. Thompson, A systematic review of statin-induced muscle problems in clinical trials, Am Heart J, vol.168, pp.6-15, 2014.

J. A. Finegold, C. H. Manisty, B. Goldacre, A. J. Barron, and D. P. Francis, What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice, Eur J Prev Cardiol, vol.21, pp.464-74, 2014.

C. B. Alonzo, Myths and facts concerning the use of statins in very old patients, Cardiovasc Hematol Disord Drug Targets, vol.11, pp.17-23, 2011.

Y. L. Yan, B. Qiu, and L. J. Hu, Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis, Eur J Clin Pharmacol, vol.69, pp.2001-2010, 2013.

Z. A. Marcum, V. Griend, J. P. Linnebur, and S. A. , FDA Drug Safety Communications: A Narrative Review and Clinical Considerations for Older Adults, Am J Geriatr Pharmacother, vol.10, pp.264-71, 2012.

W. Lo-ciganic, S. Perera, and S. L. Gray, Statin Use and Decline in Gait Speed in Community-Dwelling Older Adults, J Am Geriatr Soc, vol.63, pp.124-133, 2015.

W. Haerer, K. Delbaere, H. Bartlett, S. R. Lord, and J. Rowland, Relationships between HMGCoA reductase inhibitors (statin) use and strength, balance and falls in older people: Statins associated with impaired balance, Intern Med J, vol.42, pp.1329-1363, 2012.

M. Boetje, D. Bunout, G. Barrera, M. P. De-la-maza, L. Leiva et al., Effects of statin use on functional capacity and muscle mass in elderly women, Ageing Res, vol.2, issue.7, 2011.

D. Scott, L. Blizzard, J. Fell, and G. Jones, Statin therapy, muscle function and falls risk in community-dwelling older adults, QJM, vol.102, pp.625-658, 2009.

M. J. Tikkanen, I. Holme, and N. B. Cater, Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ?65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study), Am J Cardiol, vol.103, pp.577-82, 2009.

D. Preiss and N. Sattar, Statins and the risk of new-onset diabetes: a review of recent evidence, Curr Opin Lipidol, vol.22, pp.460-466, 2011.

N. Sattar, D. Preiss, and H. M. Murray, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, vol.375, pp.735-777, 2010.

R. D. Pandey, P. P. Gupta, D. Jha, and S. Kumar, Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs, Int J Neurosci, vol.123, pp.521-526, 2013.

B. Mcguinness, D. Craig, R. Bullock, and P. Passmore, Statins for the prevention of dementia, Cochrane Database Syst Rev, 2016.

K. J. Swiger, R. J. Manalac, R. S. Blumenthal, M. J. Blaha, and S. S. Martin, Statins and Cognition: A Systematic Review and Meta-analysis of Short-and Long-term Cognitive Effects, Mayo Clin Proc, vol.88, pp.1213-1234, 2013.

K. Richardson, M. Schoen, and B. French, Statins and Cognitive Function: A Systematic Review, Ann Intern Med, vol.159, p.688, 2013.

M. A. Omar and J. P. Wilson, FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis, Ann Pharmacother, vol.36, pp.288-95, 2002.

, Prise en charge thérapeutique du patient dyslipidémique, 2005.

N. J. Stone, J. G. Robinson, and A. H. Lichtenstein, ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, vol.129, pp.1-45, 2013.

Z. Reiner, A. L. Catapano, D. Backer, and G. , EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the, European Atherosclerosis Society

, Eur Heart J, vol.32, pp.1769-818, 2011.

S. Béliard, F. Bonnet, and B. Bouhanick, Consensus statement on the management of dyslipidaemias in adults, Ann Endocrinol, vol.78, pp.43-53, 2017.

P. Darmon, B. Bauduceau, and L. Bordier, Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2, MmM, vol.11, pp.577-593, 2017.

L. Mauff and T. , Evaluation de la pertinence de la prescription des statines chez les plus de 75 ans admis en service de court séjour gériatrique en provenance de la ville, 2017.

L. Calvet, Dépenses de santé, hospitalisations et pathologies des personnes âgées de 75 ans ou plus. DREES, 2013.

P. Latry, M. Molimard, and B. Dedieu, Adherence with statins in real-life setting is betteer when associated cardiovascular risk factors increase : a cohort study, BMC Cardiovasc Disord, vol.26, pp.11-46, 2011.

J. S. Benner, R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein et al., Long-term persistence in use of statin therapy in elderly patients, JAMA, vol.288, pp.455-61, 2002.

C. A. Jackevicius, M. Mamdani, and J. V. Tu, Adherence with statin therapy in elderly patients with and without acute coronary syndromes, JAMA, vol.288, pp.462-469, 2002.

H. Autorité-de-santé, Efficacité et efficience des hypolipémiants : une analyse centrée sur les statines, 2010.

N. K. Choudhry, R. Levin, and W. C. Winkelmayer, Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice, Heart, vol.93, pp.945-51, 2007.

T. R. Pedersen, High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial InfarctionThe IDEAL Study: A Randomized Controlled Trial, JAMA, vol.294, p.2437, 2005.

S. Pichetti, C. Sermet, B. Godman, S. M. Campbell, and L. L. Gustafsson, Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France, Appl Health Econ Health Policy, pp.205-223, 2013.

D. Rosenbaum, Intolérance et effets secondaires des statines, mt, vol.20, pp.166-71, 2014.

D. A. Redelmeier, S. H. Tan, and G. L. Booth, The treatment of unrelated disorders in patients with chronic medical diseases, N Engl J Med, vol.338, pp.516-1520, 1998.

H. Blain, P. Rambourg, L. Quellec, A. Ayach, L. Biboulet et al., Appropriate medication prescribing in older people, Rev Med Interne, vol.36, pp.667-89, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01770217

N. J. Stone, Statins in very elderly adults (debate), J Am Geriatr Soc, vol.62, pp.943-948, 2014.

M. W. Rich, Aggressive lipid management in very elderly adults : less is more, J Am Geriatr Soc, vol.62, pp.945-952, 2014.

S. Lewington, G. Whitlock, and C. R. , Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, vol.370, pp.1829-1868, 2007.

C. Conseil-scientifique-du, Quelle attitude après la nouvelle recommandation de la HAS?, 2017.

A. Desnoyer, B. Guignard, and P. O. Lang, Prescriptions médicamenteuses potentiellement inappropriées en gériatrie : quels outils utiliser pour les détecter, Press Med, vol.45, pp.957-70, 2016.

A. Boudon, F. Riat, and Y. Rassam-hasso, Polymorbidité et polypharmacie.Comment optimiser la prise en charge des patients âgés complexes, Forum Med Suisse, vol.17, pp.306-318, 2017.

O. &apos;mahony, D. , O. &apos;sullivan, D. Byrne, S. et al.,

, STOPP/START criteria for potentially inappropriate prescribing in older people: version 2, Age Ageing, vol.44, pp.213-221, 2015.

, Haute Autorité de Santé-Mettre en oeuvre la conciliation des traitements médicamenteux en établissement de santé

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses